Knott David M Jr Sells 57,578 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Knott David M Jr trimmed its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 93.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,005 shares of the company’s stock after selling 57,578 shares during the period. Knott David M Jr’s holdings in Roivant Sciences were worth $47,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ROIV. GAMMA Investing LLC lifted its stake in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after buying an additional 1,288 shares during the period. PNC Financial Services Group Inc. raised its holdings in Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after acquiring an additional 1,507 shares in the last quarter. Quarry LP lifted its position in shares of Roivant Sciences by 50.0% in the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after acquiring an additional 2,500 shares during the period. Blue Trust Inc. grew its holdings in shares of Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock worth $91,000 after purchasing an additional 6,667 shares in the last quarter. Finally, HighTower Advisors LLC bought a new stake in shares of Roivant Sciences during the fourth quarter valued at approximately $121,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $10.09 on Tuesday. The stock has a market capitalization of $7.20 billion, a price-to-earnings ratio of -67.26 and a beta of 1.26. The business’s fifty day moving average price is $10.72 and its two-hundred day moving average price is $11.38. Roivant Sciences Ltd. has a fifty-two week low of $9.92 and a fifty-two week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Research analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ROIV has been the subject of several research reports. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $17.10.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were bought at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the acquisition, the director now owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00. Following the completion of the sale, the chief operating officer now owns 732,294 shares of the company’s stock, valued at approximately $8,260,276.32. This trade represents a 12.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,395,541 shares of company stock valued at $15,028,538. Corporate insiders own 7.90% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.